Journal Article

Skipping the Biopsy: Real-World Experience of Whole-Exome Sequencing as First-Tier Testing in Pediatric Muscular Disorders

Chiu, Huei-Ching, Lee, Chung-Lin, Tu, Yuan-Rong, Lin, Hsiang-Yu, Chang, Ya-Hui, Lin, Shuan-Pei, Lo, Yun-Ting, Wu, Jun-Yi, Chuang, Chih-Kuang

2026

Overview

Muscle biopsy has long been regarded as the cornerstone for diagnosing pediatric muscular disorders; however, it is invasive and may be limited by sampling error and inconclusive histopathological findings. This study aimed to evaluate whether whole-exome sequencing (WES) can effectively replace muscle biopsy as a first-line diagnostic approach in children with suspected neuromuscular disorders. Between January 2018 and December 2025, we prospectively enrolled 47 pediatric patients presenting with clinical features suggestive of muscular disorders at a tertiary medical center in Taiwan. The cohort included patients with suspected muscular dystrophies (n = 21), congenital myopathies (n = 23), and multiplex ligation-dependent probe amplification (MLPA)-negative Duchenne muscular dystrophy (DMD; n = 3). All patients underwent WES as the initial diagnostic test without prior muscle biopsy. Trio-based analysis using parental samples was performed in 29.8% of cases. Variant interpretation followed the American College of Medical Genetics and Genomics (ACMG) guidelines. WES identified a definitive molecular diagnosis in 72.3% of patients (34/47). Diagnostic yields varied by subgroup: 100% (3/3) in MLPA-negative DMD, 71.4% (15/21) in muscular dystrophies, and 69.6% (16/23) in congenital myopathies. Pathogenic or likely pathogenic variants were detected in 31 distinct genes, including COL6A1 and COL6A3, which are associated with Ullrich congenital muscular dystrophy. Notably, 58.8% of diagnosed patients (20/34) received molecular diagnoses that differed from their initial clinical impression, encompassing conditions such as ZSWIM6-associated neurodevelopmental disorders, GJB2-related hearing loss, OCRL-associated Lowe syndrome, and various metabolic or syndromic disorders. In all three MLPA-negative DMD cases, WES identified point mutations amenable to mutation-specific therapies. No patient required a muscle biopsy for diagnostic confirmation during the study period. First-tier WES demonstrates high diagnostic utility in pediatric muscular disorders while avoiding invasive muscle biopsy. The high rate of diagnostic reclassification underscores the substantial phenotypic overlap between primary neuromuscular diseases and other neurological or systemic conditions. These findings support the early implementation of genetic testing to enable accurate diagnosis and timely initiation of targeted therapies.

• Publisher: MDPI AG,Multidisciplinary Digital Publishing Institute (MDPI)
• Subject: Adolescent / Analysis / Biopsy / Child / Child, Preschool / Children / Clinical medicine / Congenital diseases / Disease / Exome Sequencing - methods / Female / Gene mutations / Genes / Genetic disorders / Genetic screening / Genetic testing / Genetic Testing - methods / Health aspects / Humans / Infant / Kinases / Male / Medical centers / Medical genetics / Medical tests / Metabolism / Mitochondrial DNA / Muscular Diseases - diagnosis / Muscular Diseases - genetics / Muscular Diseases - pathology / Muscular Dystrophies - diagnosis / Muscular Dystrophies - genetics / Muscular dystrophy / Muscular Dystrophy, Duchenne - diagnosis / Muscular Dystrophy, Duchenne - genetics / Mutation / Neurodevelopmental disorders / Patients / Pediatrics / Prospective Studies / Work experience